Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis

被引:6
|
作者
Niu, Xiao-Wei [1 ]
Zhang, Jing-Jing [2 ]
Bai, Ming [3 ]
Peng, Yu [3 ]
Zhang, Zheng [3 ]
机构
[1] Lanzhou Univ, Clin Med Sch 1, Lanzhou, Gansu, Peoples R China
[2] Baiyin Second Peoples Hosp, Baiyin, Peoples R China
[3] Lanzhou Univ, Dept Cardiol, Hosp 1, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
关键词
Glycoprotein IIb/IIIa inhibitors; Meta-analysis; Myocardial reperfusion; Thrombectomy; Percutaneous coronary intervention; MANUAL THROMBUS ASPIRATION; PRIMARY ANGIOPLASTY; COMBINATION TREATMENT; INFARCTION; ABCIXIMAB; TIROFIBAN; PERFUSION; IMPACT; EPTIFIBATIDE; MORTALITY;
D O I
10.11909/j.issn.1671-5411.2017.10.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Suboptimal myocardial reperfusion is common in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Furthermore, it results in increased infarct size and mortality rates. We performed a meta-analysis to evaluate the role of aspiration thrombectomy (AT) combined with intracoronary administration of glycoprotein IIb/IIIa inhibitors (GPI) in the improvement of myocardial reperfusion and clinical outcomes. Methods PubMed, Embase, Web of Science, and CENTRAL databases were searched for randomized controlled trials (RCTs) investigating combined AT and intracoronary GPI treatment versus AT alone. Outcomes of interest were thrombolysis in myocardial infarction myocardial perfusion grade (TMPG), infarct size (IS) assessed by cardiac magnetic resonance imaging, left ventricular ejection fraction (LVEF), major adverse cardiac events (MACE) at short-term (<= 1 month) and long-term (6. 12 months) follow-up, and bleeding complications during the hospital stay. Results Eight trials involving 923 patients were included. Compared with AT alone, combined AT and intracoronary GPI significantly increased TMPG 3 flow (RR: 1.15, 95% CI: 1.04 to 1.26), reduced IS [mean difference (MD): -3.46, 95% CI: -5.18 to -1.73], and improved LVEF (MD: 1.44, 95% CI: 0.54 to 2.33). Furthermore, GPI use decreased the risk of MACE at long-term follow-up (RR: 0.60, 95% CI: 0.37 to 0.98). There was no significant difference between the two groups in the incidence of minor and major bleeding complications. Conclusions Our findings showed that compared with AT alone, combined AT and intracoronary GPI treatment resulted in improved myocardial reperfusion, better cardiac function, and MACE-free survival benefits at the long-term follow-up for patients with STEMI undergoing PPCI.
引用
收藏
页码:614 / 623
页数:10
相关论文
共 50 条
  • [41] The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
    Iversen, Allan
    Galatius, Soren
    Jensen, Jan S.
    CURRENT CARDIOLOGY REVIEWS, 2008, 4 (04) : 293 - 299
  • [42] Impact of routine manual aspiration thrombectomy on outcomes of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction: A meta-analysis
    Barkagan, Michael
    Steinvil, Arie
    Berchenko, Yakir
    Finkelstein, Ariel
    Keren, Gad
    Banai, Shmuel
    Halkin, Amir
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 204 : 189 - 195
  • [43] Meta-Analysis of Randomized Clinical Trials Comparing Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention and in Patients With ST-Segment Elevation Myocardial Infarction
    Nairooz, Ramez
    Sardar, Partha
    Amin, Hossam
    Swaminathan, Rajesh V.
    Kim, Luke K.
    Chatterjee, Saurav
    Feldman, Dmitriy N.
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (02) : 250 - 259
  • [44] Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: A meta-analysis of randomized clinical trials
    Lee, Michael S.
    Liao, Hsini
    Yang, Tae
    Dhoot, Jashdeep
    Tobis, Jonathan
    Fonarow, Gregg
    Mahmud, Ehtisham
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 152 (03) : 369 - 374
  • [45] Successful recanalization of an occluded coronary artery by percutaneous coronary intervention, systemic administration of tirofiban, a glycoprotein IIb/IIIa inhibitor, and intracoronary thrombolysis with alteplase
    Meyners, W
    Peters, S
    Trümmel, M
    Koehler, B
    ZEITSCHRIFT FUR KARDIOLOGIE, 2004, 93 (05): : 407 - 412
  • [46] Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary InterventionFocusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis
    Huang, Fang-Yang
    Huang, Bao-Tao
    Peng, Yong
    Liu, Wei
    Zhao, Zhen-Gang
    Wang, Peng-Ju
    Zuo, Zhi-Liang
    Zhang, Chen
    Liao, Yan-Biao
    Luo, Xiao-Lin
    Meng, Qing-Tao
    Chen, Chi
    Huang, Kai-Sen
    Chai, Hua
    Li, Qiao
    Chen, Mao
    Zhu, Ye
    ANGIOLOGY, 2015, 66 (09) : 845 - 855
  • [47] Meta-Analysis of the Long-Term Effect of Routine Aspiration Thrombectomy in Patients Undergoing Primary Percutaneous Coronary Intervention
    Mancini, Joseph G.
    Filion, Kristian B.
    Windle, Sarah B.
    Habib, Bettina
    Eisenberg, Mark J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2016, 118 (01) : 23 - 31
  • [48] Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention
    Labinaz, Marino
    Ho, Chuong
    Banerjee, Srabani
    Martin, Janet
    Chen, Stella
    Mensinkai, Shaila
    CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 (12) : 963 - 970
  • [49] Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization A Meta-Analysis of Randomized Trials Performed in the Era of Stents and Thienopyridines
    Winchester, David E.
    Wen, Xuerong
    Brearley, William D.
    Park, Ki E.
    Anderson, R. David
    Bavry, Anthony A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (10) : 1190 - 1199
  • [50] Intravenous β-blockers for patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials
    Elgendy, Islam Y.
    Elgendy, Akram Y.
    Mahmoud, Ahmed N.
    Mansoor, Hend
    Mojadidi, Mohammad K.
    Bavry, Anthony A.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 891 - 897